Status:
COMPLETED
Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation
Lead Sponsor:
University of Texas Southwestern Medical Center
Conditions:
Asthma
Eligibility:
All Genders
7-18 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the effectiveness of nebulized magnesium sulfate as a vehicle for albuterol in children with moderate to severe asthma exacerbation.
Detailed Description
Patients presenting to the Emergency Department for acute asthma exacerbation will receive standard care of up to three doses of albuterol and ipratropium bromide plus oral steroid medication. Those s...
Eligibility Criteria
Inclusion
- Patients age ≥ seven years
- Previous diagnosis of asthma or previous episode of wheezing treated with beta-agonist medication
- Able to complete bedside spirometry
- FEV1 \< 70% predicted
Exclusion
- Known allergy to magnesium sulfate
- Known contra-indication to albuterol
- Respiratory distress occurring as a result of bedside spirometry
- History of neuromuscular disease, cardiac disease, renal disease, or underlying chronic lung disease
- Pregnancy
- Use of oral steroid medication within 72 hours of presentation
- Radiographic evidence of pneumonia at presentation
- Intubation during the current encounter prior to study enrollment
- Administration of intravenous magnesium sulfate prior to study enrollment
- Prior participation in this study
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01515995
Start Date
January 1 2012
End Date
October 1 2015
Last Update
February 21 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Medical Center Dallas
Dallas, Texas, United States, 75390